Castle Biosciences Inc
NASDAQ:CSTL

Watchlist Manager
Castle Biosciences Inc Logo
Castle Biosciences Inc
NASDAQ:CSTL
Watchlist
Price: 29.81 USD 3.22% Market Closed
Market Cap: 835m USD
Have any thoughts about
Castle Biosciences Inc?
Write Note

Castle Biosciences Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Castle Biosciences Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Castle Biosciences Inc
NASDAQ:CSTL
Change in Working Capital
-$8.4m
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Change in Working Capital
-$80.4m
CAGR 3-Years
29%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Change in Working Capital
-$60m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
16%
CVS Health Corp
NYSE:CVS
Change in Working Capital
-$138.7B
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-25%
Cigna Corp
NYSE:CI
Change in Working Capital
-$2.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-18%
Laboratory Corporation of America Holdings
NYSE:LH
Change in Working Capital
-$259.2m
CAGR 3-Years
22%
CAGR 5-Years
1%
CAGR 10-Years
8%
No Stocks Found

Castle Biosciences Inc
Glance View

Market Cap
834m USD
Industry
Health Care

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.

CSTL Intrinsic Value
31.49 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Castle Biosciences Inc's Change in Working Capital?
Change in Working Capital
-8.4m USD

Based on the financial report for Sep 30, 2024, Castle Biosciences Inc's Change in Working Capital amounts to -8.4m USD.

What is Castle Biosciences Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
1%

Over the last year, the Change in Working Capital growth was 23%. The average annual Change in Working Capital growth rates for Castle Biosciences Inc have been -1% over the past three years , 1% over the past five years .

Back to Top